Date: Aug. 27th, 2022

Your Name: Hiroya Hayashi

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
4	i consumb iees	I A NONE	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	Cestimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10		XNone	
	in other board, society,		
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
	None		
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022 Your Name: Yu Kataoka

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	AMCA	
5	Payment or honoraria for	Nipro	honoraria
	lectures, presentations,	Abbott	honoraria
	speakers bureaus,	Kowa	honoraria
	manuscript writing or educational events	Amgen	honoraria
	educational events	Sanofi	honoraria
		Astellas	honoraria
		Takeda, Daiichi-Sankyo	honoraria
	Devine and fair average	V None	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Please summarize the above conflict of interest in the following box:

I received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda and Daiichi-Sankyo.

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: Aug. 27th, 2022 Your Name: Kota Murai

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	Cestimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10		XNone	
	in other board, society,		
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
	None		
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Kenichiro Sawada

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
Г			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Aug. 27th, 2022

Your Name: Takamasa Iwai

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Γherapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	Cestimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10		XNone	
	in other board, society,		
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
	None		
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Hideo Matama

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022 Your Name: Satoshi Honda

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
Δ	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Masashi Fujino

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
Δ	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Shuichi Yoneda

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
З	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Kensuke Takagi

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Fumiyuki Otsuka

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
O	testimony		
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
4.1	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descint of aguingment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
12		V None	
13	Other financial or non- financial interests	XNone	
	inialiciai initerests		
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
None			
	None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Yasuhide Asaumi

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
Δ	Consulting fees	X None	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
6	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data Safety Monitoring Board or	XNone		
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy group, paid or unpaid			
11		V None		
11	Stock or stock options	XNone		
12	Pecaint of aquinment	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	^_NONE		
	services			
13	Other financial or non-	X None		
13	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
_				
None.				

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022

Your Name: Yasuhiro Izumiya

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment, materials, drugs, medical	X_None		
	writing, gifts or other			
	services			
13	Other financial or non- financial interests	X None		
Ple	Please summarize the above conflict of interest in the following box:			
Г				
None.				
L				

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Aug. 27th, 2022 Your Name: Daiju Fukuda

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
6	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data Safety Monitoring Board or	XNone		
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy group, paid or unpaid			
11		V None		
11	Stock or stock options	XNone		
12	Pecaint of aquinment	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	^_NONE		
	services			
13	Other financial or non-	X None		
13	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
_				
None.				

Please place an "X" next to the following statement to indicate your agreement:

Date: Aug. 27th, 2022 Your Name: Teruo Noguchi

Manuscript Title: Cardiovascular and Bleeding Risks of Inactive Cancer in Patients with Acute Myocardial Infarction Who

Received Primary Percutaneous Coronary Intervention Using Drug-eluting Stent and Dual/Triple Antithrombotic

Therapy

Manuscript number (if known): CDT-22-306

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
6	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data Safety Monitoring Board or	XNone		
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy group, paid or unpaid			
11		V None		
11	Stock or stock options	XNone		
12	Pecaint of aquinment	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	^_NONE		
	services			
13	Other financial or non-	X None		
13	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
_				
None.				

Please place an "X" next to the following statement to indicate your agreement: